These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35790696)

  • 1. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
    Fukumoto S; Murata T; Osuga Y; Pollock RF
    Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
    Auerbach M; Achebe MM; Thomsen LL; Derman RJ
    Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.
    Zhang F; Shen A; Ahmed W; Pollock RF
    Adv Ther; 2024 Nov; 41(11):4191-4204. PubMed ID: 39292421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric derisomaltose for the treatment of iron deficiency anemia with postpartum hemorrhage: Results of a single-arm, open-label, phase 3 study in Japan.
    Sugimura M; Ohtani Y; Tamai S; Kishimoto U; Ito N
    J Obstet Gynaecol Res; 2023 Mar; 49(3):946-955. PubMed ID: 36653310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study.
    Kawabata H; Tamura T; Tamai S; Takahashi T; Kato J;
    Int J Hematol; 2022 Dec; 116(6):846-855. PubMed ID: 35867202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis].
    Ding SX; Zhao YH; Wang T; Guan J; Xing LM; Liu H; Wang GJ; Wang XM; Wu YH; Qu W; Song J; Wang HQ; Li LJ; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):178-183. PubMed ID: 38604795
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia.
    Derman R; Roman E; Smith-Nguyen GN; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2018 Jun; 93(6):E148-E150. PubMed ID: 29569727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.